Brigatinib-analog - CAS# 1197958-12-5 nd Library of Histone Demethylase C(CCN1CCN(CCOC(C2C=CC=CC=2)C2C=CC=CC=2)CC1)C1C=CC=CC=1

C(CCN1CCN(CCOC(C2C=CC=CC=2)C2C=CC=CC=2)CC1)C1C=CC=CC=1

PubMed Central PMCID: PMC2362948

is an Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect

H-PGDS INHIBITOR I has no code name

Cell viability studies are performed in a variety of mammalian cell lines to compare the in vitro antiproliferative effects of MLN2238 with Bortezomib

Brigatinib-analog - CAS# 1197958-12-5 nd Library of Histone Demethylase C(CCN1CCN(CCOC(C2C=CC=CC=2)C2C=CC=CC=2)CC1)C1C=CC=CC=1Brigatinib analog, CAS No. 1197958 12 5, is an orally active, potent and selective anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) inhibitor. Brigatinib analog is structurally related to Brigatinib (AP 26113). Brigatinib analog binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and